focus -WSS

focus

author：entertainment 2025-10-01 02:13:39 - browse：87

Adam's take main illustration — Molly Ferguson/STAT

Some day-after thoughts on Bristol Myers Squibb acquiring Mirati Therapeutics:

A take-under deal feels meh for biotech sector sentiment.Bristol is paying $58 per share in cash for Mirati, which closed Friday at $60. Granted, Mirati was trading in the $30 range in September, so from there, the roughly 50% premium isn’t terrible. But as Mizuho strategist Jared Holz pointed out, investors would liked to have seen Mirati go for $75-$100 per share.

With the closely watched XBI biotech index down 13% for the year, every M&A deal helps improve sentiment, but this one — maybe just a little. Bristol is paying $4.8 billion in cash to acquire Mirati, or $3.7 billion after accounting for Mirati’s cash. It’s a small bolt-on acquisition for Bristol, which isn’t overpaying.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： Sophia Smith scores twice for US in in 3

focus

WSS

FDA approves first blood sugar monitor without finger pricks

What Henrietta Lacks's story taught me about my role as a doctor

My chronic pain journey would have been easier knowing 5 things % STAT

NIH director takes cautious approach to Biden drug pricing priority

Think you might have Covid

The response to Covid

focus

focus

knowledge

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Elizabeth Holmes banned from government health programs

Cancer drug shortages should be causing more outrage

Test for long Covid? Researchers find new clue in blood samples

Drug repurposing or repositioning? The language matters

What Henrietta Lacks's story taught me about my role as a doctor

Peter Hotez and the public health issue of online harassment

New requirements coming in 2024 for Americans traveling to Europe

After affirmative action ruling, medical educators look to 'holistic review'

4 missing after record

focus

How a key Senate committee is planning to regulate PBMs

Woman found dead after suspected bear encounter near Yellowstone, wildlife officials say

Men with early prostate cancer can safely opt out of treatment

The response to Covid

My chronic pain journey would have been easier knowing 5 things % STAT

My chronic pain journey would have been easier knowing 5 things % STAT

knowledge

leisure time

focus

focus